Quinolone immediate hypersensitivity due to topical ophthalmic preparations: a case report and review of literature.
Mas-related G-protein coupled receptor X2
basophil activation test
eyedrop
immediate hypersensitivity
quinolone
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
28
07
2020
accepted:
01
10
2020
pubmed:
29
10
2020
medline:
15
5
2021
entrez:
28
10
2020
Statut:
ppublish
Résumé
Ophthalmic quinolone preparations are widely used for the treatment of eye diseases; however, there are only a few reported cases of immediate hypersensitivity due to such medications. Here, we present a case of immediate hypersensitivity induced by an ophthalmic administration of quinolones in a 20-year-old female with bacterial conjunctivitis. The results of skin prick and basophil activation tests suggest that it involved a type Ib reaction associated with Mas-related G-protein coupled receptor X2. The present case cautions us to be aware of quinolone immediate hypersensitivity caused by topical ophthalmic preparations, which can easily be overlooked, because it may predict severe hypersensitivity reactions to systemic administration.
Identifiants
pubmed: 33112013
doi: 10.1111/1346-8138.15669
doi:
Substances chimiques
Quinolones
0
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
389-391Subventions
Organisme : Ministry of Education, Culture, Sports, Science and Technology
ID : 24390276
Organisme : Ministry of Health, Labor and Welfare of Japan
Informations de copyright
© 2020 Japanese Dermatological Association.
Références
Benitez-Del-Castillo J, Verboven Y, Stroman D et al. The role of topical moxifloxacin, a new antibacterial in Europe, in the treatment of bacterial conjunctivitis. Clin Drug Investig 2011; 31: 543-57.
McGee EU, Samuel E, Boronea B et al. Quinolone allergy. Pharmacy (Basel) 2019; 7: 97.
Tayman C, Mete E, Catal F et al. Anaphylactic reaction due to cyclopentolate in a 4-year-old child. J Investig Allergol Clin Immunol 2010; 20: 347-348.
Saito M, Nakada T. Contact urticaria syndrome from eye drops: levofloxacin hydrate ophthalmic solution. J Dermatol 2013; 40: 130-131.
Fujiwara Y, Inomata N, Ishida S et al. Contact urticaria syndrome caused by sulfamethoxazole sodium contained in eye drops. Contact Dermatitis 2017; 77: 56-57.
Ullman MA, Midgley KJ, Kim J et al. Anaphylactic reaction secondary to topical preoperative moxifloxacin. J Cataract Refract Surg 2016; 42: 1836-1837.
Kanda Y, Kayama T, Okamoto S et al. Post-marketing surveillance of levofloxacin 0.5% ophthalmic solution for external ocular infections. Drugs R D 2012; 12: 177-185.
Mohan N, Gupta V, Tandon R et al. Topical ciprofloxacin-dexamethasone combination therapy after cataract surgery: randomized controlled clinical trial. J Cataract Refract Surg 2001; 27: 1975-1978.
Porebski G, Kwiecien K, Pawica M et al. Mas-Related G Protein-Coupled Receptor-X2 (MRGPRX2) in Drug Hypersensitivity Reactions. Front Immunol 2018; 9: 3027.
Subramanian H, Gupta K, Ali H. Roles of Mas-related G protein-coupled receptor X2 on mast cell-mediated host defense, pseudoallergic drug reactions, and chronic inflammatory diseases. J Allergy Clin Immunol 2016; 138: 700-710.
Wedi B, Gehring M, Kapp A. The pseudoallergen receptor MRGPRX2 on peripheral blood basophils and eosinophils: expression and function. Allergy 2020; 75(9): 2229-2242.
Doña I, Pérez-Sánchez N, Salas M et al. Clinical characterization and diagnostic approaches for patients reporting hypersensitivity reactions to quinolones. J Allergy Clin Immunol Pract 2020; 8(8): 2707-2714.
Weiler CR. Mastocytosis, Quinolones, MRGPRX2, and Anaphylaxis. J Allergy Clin Immunol Pract 2019; 7: 2091-2092.
Spoerl D, Nigolian H, Czarnetzki C et al. Reclassifying anaphylaxis to neuromuscular blocking agents based on the presumed patho-mechanism: IgE-mediated, pharmacological adverse reaction or "Innate Hypersensitivity"? Int J Mol Sci 2017; 18(6): 1223.